S95011 concentrate for solution for infusion (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04605978 (ClinicalTrials.gov) | December 7, 2020 | 19/10/2020 | Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients | A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study | Primary Sjögren's Syndrome | Drug: S95011 concentrate for solution for infusion;Drug: Placebo concentrate for solution for infusion | Institut de Recherches Internationales Servier | ADIR, a Servier Group company | Not yet recruiting | 18 Years | 75 Years | All | 45 | Phase 2 | United States;Australia;Canada;France;Germany;Hungary;Spain;United Kingdom |